The guidance includes approaches to expanding the coverage, quality and impact of existing social protection programs to people affected by TB.

The World Health Organization (WHO) released its updated Bacterial Priority Pathogens List (BPPL) 2024, featuring 15 families of antibiotic-resistant bacteria grouped into critical, high and medium categories for prioritization. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR).

WHO releases consolidated guidelines on HIV-associated TB providing a single comprehensive source for the latest evidence-informed TB/HIV recommendations.

On 14 May 2024, the World Health Organization (WHO) will convene a civil society Town Hall in close collaboration with the WHO Civil Society Task Force on TB. The Town Hall will focus on the urgent actions needed to translate the Political Declaration of the 2023 UN High-Level Meeting on TB into action, through the civil society lens and community empowerment.

The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners. 

The World Health Organization (WHO) Global Tuberculosis Programme is launching a call for expressions of interest, seeking collaborators to design and conduct a series of youth engagement campaigns in selected countries on ending TB.

9 April 2024 — In a Rapid Communication issued today, the World Health Organization (WHO) is announcing updates on co-administration of treatment for drug-resistant tuberculosis and hepatitis C (HCV). The evidence suggests that concomitant treatment for HCV and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) is feasible, with potential benefits outweighing the harms. Co-administration may increase MDR/RR-TB treatment success and reduce failures, losses to follow-up, and deaths. Adherence support for HCV treatment during MDR/RR-TB treatment is also acknowledged.

On World TB Day, WHO is calling for action on several fronts to ensure that the commitments made to end TB are achieved. A special newsletter edition compiles all WHO advocacy activities and key resources released in the lead-up to World TB Day.

The World Health Organization (WHO) has coordinated the selection of new members to the WHO Civil Society Task Force on Tuberculosis (CSTF-TB) for the period 2024 - 2025. Building on achievements of the CSTF-TB to date, the Task Force will continue to serve as a platform for discussion and exchange with WHO, advising WHO on leveraging engagement with civil society and affected communities at all levels to implement the Guidance on engagement of communities and civil society to end tuberculosis and accelerate progress towards ending TB.

On World TB Day, WHO is calling for action on several fronts to ensure that the commitments made to end TB are achieved. WHO releases an advocacy and communications World TB Day campaign package.